NFE2L2 and hepatocellular carcinoma: Therefore, an idea can be the development of stimuli-responsive nanoparticles capable of releasing Nrf2 inhibitors in response to changes in the tumor microenvironment to provide specific delivery to HCC cells not hepatocytes.